CLAIMS

1. A compound of formula (I)



(I)

wherein each of Ar^1 , Ar^2, and Ar^3 is independently selected $(C_6\text{-}C_{10})$aryl ring system or a (5- to 10-membered) heteroaryl ring system, wherein any aryl or heteroaryl ring system of Ar^1, Ar^2, or Ar^3 is optionally fused with a cycloalkyl or a heterocyclyl ring; wherein any aryl or heteroaryl of Ar^1, Ar^2, or Ar^3 is each optionally independently mono- or multi-substituted with up to three substituents selected from the group consisting of $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl, halo, halo$(C_1\text{-}C_4)$alkyl, OH, monohydroxy $(C_1\text{-}C_4)$alkyl, dihydroxy$(C_2\text{-}C_4)$alkyl, monohydroxy$(C_1\text{-}C_4)$alkoxy, dihydroxy $(C_2\text{-}C_4)$ alkoxy, $(C_1\text{-}C_4)$alkoxy, $(C_2\text{-}C_6)$acyl, $(C_1\text{-}C_6)$alkoxycarbonyl$(CH_2)_{0\text{-}2}$, carboxy $(CH_2)_{0\text{-}2}$, oxo, cyano, $NR_2(CH_2)_{1\text{-}2}$, $NR_2C(=O)(CH_2)_{0\text{-}2}$, $NR_2C(=O)(CH_2)_{0\text{-}2}O(CH_2)_{0\text{-}2}$, $(C_2\text{-}C_4)$ $C(=O)N(R)$, $(C_1\text{-}C_4)OC(=O)N(R)$, C=NOR, $(C_3\text{-}C_{10})$cycloalkyl, (5- to 10-membered) heterocyclyl, $(C_6\text{-}C_{10})$aryl, and (5- to 10-membered) heteroaryl; wherein any cyclo-alkyl, heterocyclyl, aryl or heteroaryl substituent of Ar^1, Ar^2, or Ar^3 is itself optionally substituted with up to three secondary substituents selected from the group consisting of $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl, halo, halo$(C_1\text{-}C_4)$alkyl, OH, monohydroxyl $(C_1\text{-}C_4)$alkyl, dihydroxy$(C_2\text{-}C_4)$alkyl, monohydroxy$(C_1\text{-}C_4)$alkoxy, dihydroxy $(C_2\text{-}C_4)$ alkoxy, $(C_1\text{-}C_4)$alkoxy, $(C_2\text{-}C_6)$acyl, $(C_1\text{-}C_6)$alkoxycarbonyl$(CH_2)_{0\text{-}2}$, carboxy $(CH_2)_{0\text{-}2}$, oxo, cyano, $NR_2(CH_2)_{0\text{-}2}$, $NR_2C(=O)(CH_2)_{0\text{-}2}$, $NR_2C(=O)(CH_2)_{0\text{-}2}O(CH_2)_{0\text{-}2}$, $(C_1\text{-}C_4)$ $C(=O)N(R)$,($C_1\text{-}C_4)OC(=O)N(R)$, and C=NOR;

each R is independently H, $(C_1\text{-}C_4)$alkyl, hydroxy$(C_2\text{-}C_4)$alkyl, cyano, or $((C_1\text{-}C_4)$alkyl-O$)_{0\text{-}2}(C_1\text{-}C_4)$alkyl, or two R groups together with an atom to which they are both joined can form a ring;

each R' is independently H, $(C_1\text{-}C_4)$alkyl, hydroxy$(C_2\text{-}C_4)$alkyl, $(CH_2)_{0\text{-}2}C(=O)$ $O(C_1\text{-}C_4)$alkyl, or $(C_3\text{-}C_6)$cycloalkyl;

X is a bond, $(CH_2)_{1\text{-}2}$, $(CH_2)_{0\text{-}2}N(R)(CH_2)_{0\text{-}2}$, $(CH_2)_{0\text{-}2}O(CH_2)_{0\text{-}2}$, $(CH_2)_{0\text{-}2}N(R)$ $C(=O)(CH_2)_{0\text{-}2}$, $(CH_2)_{0\text{-}2}C(=O)N(R)(CH_2)_{0\text{-}2}$, $(CH_2)_{0\text{-}2}N(R)C(=O)O(CH_2)_{0\text{-}2}$, or $(CH_2)_{0\text{-}2}$ $OC(=O)N(R)(CH_2)_{0\text{-}2}$;

L is a bond, NR, C(=O), SO_2, C(=NR), $C(=O)CR_2$, C(=O)CH(N(R)C(=O)(C_1-

C_4)alkyl, C(=O)CH(N(R)C(=O)O(C_1-C_4)alkyl, C(=O)CH(NR_2), C(=O)CR(halo), or is  , or  wherein wavy lines indicate points of bonding or a pharmaceutically acceptable salt thereof and when X and L are bonds, Ar^1, Ar^2, and Ar^3 are not identical.

2. A compound of claim 1 of formula (IA)



(IA)

wherein when each of Ar^1, Ar^2, and Ar^3 is independently selected as aryl; X, L, R, and R' are as defined in claim 1.

3. The compound of claim 2, wherein X is NR and L is a bond or is C(=O) or each of Ar^1, Ar^2, and Ar^3 is phenyl.

4. A compound of claim 1 of formula (IB)



(IB)

wherein when Ar^1 and Ar^2 are independently selected aryl and Ar^3 is heteroaryl; X, L, R, and R' are as defined in claim 1.

5. The compound of claim 4, wherein X is NR and L is a bond or is C(=O) or Ar^3 is pyridyl or quinolyl or Ar^1 and Ar^3 are phenyl.

6. A compound of claim 1 of formula (IC)



(IC)

wherein when Ar^1 is aryl, Ar^2 and Ar^3 are independently selected as heteroaryl; X, L, R, and R' are as defined in claim 1.

7. A compound of claim 1 of formula (ID)



(ID)

wherein when Ar^1 and Ar^2 are independently selected aryl, and Ar^3 is heteroaryl; X, L, R, and R' are as defined in claim 1.

8. The compound of claim 7, wherein X is NR and L is a bond or is C(=O) or Ar^1 and Ar^3 are phenyl, Ar^2 is pyridyl or quinolyl, or any combination thereof.

9. A compound of claim 1 of formula (IE)



(IE)

wherein when Ar^1 and Ar^3 are independently selected heteroaryl, and Ar^2 is aryl; X, L, R, and R' are as defined in claim 1.

10. The compound of either claim 6 or claim 9, wherein X is NR and L is a bond or is C(=O), or Ar^2 is phenyl, Ar^1 is pyridyl or quinolyl, Ar^3 is pyridyl or quinolyl, or any combination thereof.

11. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

12. A compound of any one of claims 1 to 10, or a pharmaceutical composition of claim 11, for use as a medicament.

13. Use of a compound of any one of claims 1 to 10, or a pharmaceutical composition of claim 11 in the manufacture of a medicament for the treatment of a cardiopulmonary disease in a patient afflicted therewith.

14. A compound selected from:




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





























,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,






,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,









,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,







 ,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  ,  v,

 ,  ,  ,  ,

 ,  ,  ,  ,






,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



















































































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




























,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



, for use in the treatment of a cardiopulmonary disease in a patient afflicted therewith.

15. Use of a compound selected from




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,













































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,























,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,











































































































































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,













































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,
















































,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,
















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



in the manufacture of a medicament for the treatment of cardiopulmonary disease in a patient afflicted therewith.

16. The use of claim 13 or claim 15, wherein the disease is asthma or a chronic obstructive pulmonary disease or comprises sepsis; or is coronary atherosclerosis; or comprises a clinical syndrome characterized by bronchoconstriction, pulmonary fibrosis, coronary artery constriction, cytokine amplification by dendritic cells, or the generation of disseminated intravascular coagulopathy; or comprises inflammation by influenza infection; or is cardiovascular disease, hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, pulmonary hypertension, mesothelioma, ventricular conduction abnormalities, complete heart block, adult respiratory distress syndrome, sepsis syndrome, idiopathic pulmonary fibrosis, scleroderma, systemic sclerosis, retroperitoneal fibrosis, prevention of keloid formation, or cirrhosis.